Aktuellt
SENASTE
Cantargia reported their Q1 this morning with an operating loss of SEK -73.2m, 45% more than we expected (SEK -50.5m) and up 83% from last year (SEK -39.9m). The increased spending is attributable to the increased investments in research and development; the extension of the CANFOUR phase II study and the initiation of more value-adding studies to broaden Cantargia’s oncology pipeline as well as in autoimmune/inflammatory diseases. We will address the recent CMD in our review tomorrow.
LÄS MER
